BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,595,236 | $1,874,459 | $1,566,615 | $1,559,505 |
| - Cash | $0 | $88,525 | $105,190 | $104,713 |
| + Debt | $0 | $738,917 | $794,985 | $808,742 |
| Enterprise Value | $1,595,236 | $2,524,851 | $2,256,410 | $2,263,534 |
| Revenue | $159,395 | $163,353 | $145,534 | $131,534 |
| % Growth | -2.4% | 12.2% | 10.6% | – |
| Gross Profit | $156,873 | $160,555 | $140,966 | $125,403 |
| % Margin | 98.4% | 98.3% | 96.9% | 95.3% |
| EBITDA | $32,126 | $28,397 | $24,583 | -$1,233 |
| % Margin | 20.2% | 17.4% | 16.9% | -0.9% |
| Net Income | $12,899 | $5,085 | $32 | -$26,795 |
| % Margin | 8.1% | 3.1% | 0% | -20.4% |
| EPS Diluted | 0.059 | 0.02 | 0 | -0.13 |
| % Growth | 193.5% | – | 100% | – |
| Operating Cash Flow | $41,111 | $41,302 | -$27,517 | -$5,213 |
| Capital Expenditures | -$1,344 | -$179 | -$143 | -$675 |
| Free Cash Flow | $39,767 | $41,123 | -$27,660 | -$5,888 |